Cargando…

Inhibition of 12/15-Lipoxygenase Protects Against β-Cell Oxidative Stress and Glycemic Deterioration in Mouse Models of Type 1 Diabetes

Islet β-cell dysfunction and aggressive macrophage activity are early features in the pathogenesis of type 1 diabetes (T1D). 12/15-Lipoxygenase (12/15-LOX) is induced in β-cells and macrophages during T1D and produces proinflammatory lipids and lipid peroxides that exacerbate β-cell dysfunction and...

Descripción completa

Detalles Bibliográficos
Autores principales: Hernandez-Perez, Marimar, Chopra, Gaurav, Fine, Jonathan, Conteh, Abass M., Anderson, Ryan M., Linnemann, Amelia K., Benjamin, Chanelle, Nelson, Jennifer B., Benninger, Kara S., Nadler, Jerry L., Maloney, David J., Tersey, Sarah A., Mirmira, Raghavendra G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5652601/
https://www.ncbi.nlm.nih.gov/pubmed/28842399
http://dx.doi.org/10.2337/db17-0215
_version_ 1783273088163512320
author Hernandez-Perez, Marimar
Chopra, Gaurav
Fine, Jonathan
Conteh, Abass M.
Anderson, Ryan M.
Linnemann, Amelia K.
Benjamin, Chanelle
Nelson, Jennifer B.
Benninger, Kara S.
Nadler, Jerry L.
Maloney, David J.
Tersey, Sarah A.
Mirmira, Raghavendra G.
author_facet Hernandez-Perez, Marimar
Chopra, Gaurav
Fine, Jonathan
Conteh, Abass M.
Anderson, Ryan M.
Linnemann, Amelia K.
Benjamin, Chanelle
Nelson, Jennifer B.
Benninger, Kara S.
Nadler, Jerry L.
Maloney, David J.
Tersey, Sarah A.
Mirmira, Raghavendra G.
author_sort Hernandez-Perez, Marimar
collection PubMed
description Islet β-cell dysfunction and aggressive macrophage activity are early features in the pathogenesis of type 1 diabetes (T1D). 12/15-Lipoxygenase (12/15-LOX) is induced in β-cells and macrophages during T1D and produces proinflammatory lipids and lipid peroxides that exacerbate β-cell dysfunction and macrophage activity. Inhibition of 12/15-LOX provides a potential therapeutic approach to prevent glycemic deterioration in T1D. Two inhibitors recently identified by our groups through screening efforts, ML127 and ML351, have been shown to selectively target 12/15-LOX with high potency. Only ML351 exhibited no apparent toxicity across a range of concentrations in mouse islets, and molecular modeling has suggested reduced promiscuity of ML351 compared with ML127. In mouse islets, incubation with ML351 improved glucose-stimulated insulin secretion in the presence of proinflammatory cytokines and triggered gene expression pathways responsive to oxidative stress and cell death. Consistent with a role for 12/15-LOX in promoting oxidative stress, its chemical inhibition reduced production of reactive oxygen species in both mouse and human islets in vitro. In a streptozotocin-induced model of T1D in mice, ML351 prevented the development of diabetes, with coincident enhancement of nuclear Nrf2 in islet cells, reduced β-cell oxidative stress, and preservation of β-cell mass. In the nonobese diabetic mouse model of T1D, administration of ML351 during the prediabetic phase prevented dysglycemia, reduced β-cell oxidative stress, and increased the proportion of anti-inflammatory macrophages in insulitis. The data provide the first evidence to date that small molecules that target 12/15-LOX can prevent progression of β-cell dysfunction and glycemic deterioration in models of T1D.
format Online
Article
Text
id pubmed-5652601
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher American Diabetes Association
record_format MEDLINE/PubMed
spelling pubmed-56526012018-11-01 Inhibition of 12/15-Lipoxygenase Protects Against β-Cell Oxidative Stress and Glycemic Deterioration in Mouse Models of Type 1 Diabetes Hernandez-Perez, Marimar Chopra, Gaurav Fine, Jonathan Conteh, Abass M. Anderson, Ryan M. Linnemann, Amelia K. Benjamin, Chanelle Nelson, Jennifer B. Benninger, Kara S. Nadler, Jerry L. Maloney, David J. Tersey, Sarah A. Mirmira, Raghavendra G. Diabetes Pharmacology and Therapeutics Islet β-cell dysfunction and aggressive macrophage activity are early features in the pathogenesis of type 1 diabetes (T1D). 12/15-Lipoxygenase (12/15-LOX) is induced in β-cells and macrophages during T1D and produces proinflammatory lipids and lipid peroxides that exacerbate β-cell dysfunction and macrophage activity. Inhibition of 12/15-LOX provides a potential therapeutic approach to prevent glycemic deterioration in T1D. Two inhibitors recently identified by our groups through screening efforts, ML127 and ML351, have been shown to selectively target 12/15-LOX with high potency. Only ML351 exhibited no apparent toxicity across a range of concentrations in mouse islets, and molecular modeling has suggested reduced promiscuity of ML351 compared with ML127. In mouse islets, incubation with ML351 improved glucose-stimulated insulin secretion in the presence of proinflammatory cytokines and triggered gene expression pathways responsive to oxidative stress and cell death. Consistent with a role for 12/15-LOX in promoting oxidative stress, its chemical inhibition reduced production of reactive oxygen species in both mouse and human islets in vitro. In a streptozotocin-induced model of T1D in mice, ML351 prevented the development of diabetes, with coincident enhancement of nuclear Nrf2 in islet cells, reduced β-cell oxidative stress, and preservation of β-cell mass. In the nonobese diabetic mouse model of T1D, administration of ML351 during the prediabetic phase prevented dysglycemia, reduced β-cell oxidative stress, and increased the proportion of anti-inflammatory macrophages in insulitis. The data provide the first evidence to date that small molecules that target 12/15-LOX can prevent progression of β-cell dysfunction and glycemic deterioration in models of T1D. American Diabetes Association 2017-11 2017-08-25 /pmc/articles/PMC5652601/ /pubmed/28842399 http://dx.doi.org/10.2337/db17-0215 Text en © 2017 by the American Diabetes Association. http://www.diabetesjournals.org/content/licenseReaders may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.
spellingShingle Pharmacology and Therapeutics
Hernandez-Perez, Marimar
Chopra, Gaurav
Fine, Jonathan
Conteh, Abass M.
Anderson, Ryan M.
Linnemann, Amelia K.
Benjamin, Chanelle
Nelson, Jennifer B.
Benninger, Kara S.
Nadler, Jerry L.
Maloney, David J.
Tersey, Sarah A.
Mirmira, Raghavendra G.
Inhibition of 12/15-Lipoxygenase Protects Against β-Cell Oxidative Stress and Glycemic Deterioration in Mouse Models of Type 1 Diabetes
title Inhibition of 12/15-Lipoxygenase Protects Against β-Cell Oxidative Stress and Glycemic Deterioration in Mouse Models of Type 1 Diabetes
title_full Inhibition of 12/15-Lipoxygenase Protects Against β-Cell Oxidative Stress and Glycemic Deterioration in Mouse Models of Type 1 Diabetes
title_fullStr Inhibition of 12/15-Lipoxygenase Protects Against β-Cell Oxidative Stress and Glycemic Deterioration in Mouse Models of Type 1 Diabetes
title_full_unstemmed Inhibition of 12/15-Lipoxygenase Protects Against β-Cell Oxidative Stress and Glycemic Deterioration in Mouse Models of Type 1 Diabetes
title_short Inhibition of 12/15-Lipoxygenase Protects Against β-Cell Oxidative Stress and Glycemic Deterioration in Mouse Models of Type 1 Diabetes
title_sort inhibition of 12/15-lipoxygenase protects against β-cell oxidative stress and glycemic deterioration in mouse models of type 1 diabetes
topic Pharmacology and Therapeutics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5652601/
https://www.ncbi.nlm.nih.gov/pubmed/28842399
http://dx.doi.org/10.2337/db17-0215
work_keys_str_mv AT hernandezperezmarimar inhibitionof1215lipoxygenaseprotectsagainstbcelloxidativestressandglycemicdeteriorationinmousemodelsoftype1diabetes
AT chopragaurav inhibitionof1215lipoxygenaseprotectsagainstbcelloxidativestressandglycemicdeteriorationinmousemodelsoftype1diabetes
AT finejonathan inhibitionof1215lipoxygenaseprotectsagainstbcelloxidativestressandglycemicdeteriorationinmousemodelsoftype1diabetes
AT contehabassm inhibitionof1215lipoxygenaseprotectsagainstbcelloxidativestressandglycemicdeteriorationinmousemodelsoftype1diabetes
AT andersonryanm inhibitionof1215lipoxygenaseprotectsagainstbcelloxidativestressandglycemicdeteriorationinmousemodelsoftype1diabetes
AT linnemannameliak inhibitionof1215lipoxygenaseprotectsagainstbcelloxidativestressandglycemicdeteriorationinmousemodelsoftype1diabetes
AT benjaminchanelle inhibitionof1215lipoxygenaseprotectsagainstbcelloxidativestressandglycemicdeteriorationinmousemodelsoftype1diabetes
AT nelsonjenniferb inhibitionof1215lipoxygenaseprotectsagainstbcelloxidativestressandglycemicdeteriorationinmousemodelsoftype1diabetes
AT benningerkaras inhibitionof1215lipoxygenaseprotectsagainstbcelloxidativestressandglycemicdeteriorationinmousemodelsoftype1diabetes
AT nadlerjerryl inhibitionof1215lipoxygenaseprotectsagainstbcelloxidativestressandglycemicdeteriorationinmousemodelsoftype1diabetes
AT maloneydavidj inhibitionof1215lipoxygenaseprotectsagainstbcelloxidativestressandglycemicdeteriorationinmousemodelsoftype1diabetes
AT terseysaraha inhibitionof1215lipoxygenaseprotectsagainstbcelloxidativestressandglycemicdeteriorationinmousemodelsoftype1diabetes
AT mirmiraraghavendrag inhibitionof1215lipoxygenaseprotectsagainstbcelloxidativestressandglycemicdeteriorationinmousemodelsoftype1diabetes